KOL | Paul HaluskaMayo Clinic Rochester c/o Merck Corporation, 126 E. Lincoln Ave Rahway, New Jersey, 07065 USA | Mayo Clinic Department of Medical Oncology Rochester Minnesota USA |
KOL Resume for Paul Haluska
| Year | |
|---|---|
| 2021 | Mayo Clinic Rochester c/o Merck Corporation, 126 E. Lincoln Ave Rahway, New Jersey, 07065 USA |
| 2013 | Mayo Clinic Department of Medical Oncology Rochester Minnesota USA |
Prominent publications by Paul Haluska
KOL-Index: 42 . I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a monoclonal antibody designed to bind and inhibit function of the type I insulin-like growth factor receptor (IGF-1R). Ganitumab was tested in combination with metformin and paclitaxel (PGM) followed by AC compared to standard-of-care alone. While ...
Key People For Purkinje Cell
Top KOLs in the world
Select a search phrase purkinje cells , purkinje cell , purkinje cells pcs , purkinje cell degeneration , purkinje cell loss
Paul Haluska:Expert Impact
Concepts for whichPaul Haluskahas direct influence:Purkinje cell, Presenting symptom, Standard neoadjuvant therapy, Ganitumab metformin, Pca1igg autoantibodies, Multifocal neuropathy, Development predictive biomarkers.
Paul Haluska:KOL impact
Concepts related to the work of other authors for whichfor which Paul Haluska has influence:Autoimmune pain, Rad51 gene expression, Peripheral neuropathies, Aggressive biology, Cancer drug resistance, Rppa proteomic analysis, Protein array.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |